Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial
机构：[1]Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute/TheAffiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China四川省肿瘤医院[2]MedicalOncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China[3]Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, China[4]Medical Oncology, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China四川省肿瘤医院[5]Gastrointestinal Cancer Center,Chongqing University Cancer Hospital, Chongqing, China
第一作者机构：[1]Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute/TheAffiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China
推荐引用方式(GB/T 7714)：
Jin Y.,Han Y.,Zhang L.,et al.Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial[J].ANNALS OF ONCOLOGY.2021,32:S546-S547.doi:10.1016/j.annonc.2021.08.945.
APA：
Jin, Y.,Han, Y.,Zhang, L.,Jin, Y.&Sun, H..(2021).Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial.ANNALS OF ONCOLOGY,32,
MLA：
Jin, Y.,et al."Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial".ANNALS OF ONCOLOGY 32.(2021):S546-S547
医学